SB 4426, the “Safeguarding The Overall Protection of Minors Act” or “STOP Act,” would prohibit any person from knowingly performing, attempting to perform, conspiring to perform, or aiding and abetting a “gender transition procedure” on a minor when the conduct involves interstate commerce or occurs in U.S. territorial jurisdiction. The bill defines gender transition procedures broadly to include puberty blockers, cross-sex hormones, and a wide range of surgical and cosmetic procedures, while carving out exceptions for treatment of disorders of sex development, precocious puberty, emergency medical care for unrelated physical illness or injury, and certain restorative procedures after prior transition-related treatment.
The bill would create a federal enforcement scheme under the Secretary of Health and Human Services, including civil monetary penalties of at least $100,000 per violation, collection actions by the Attorney General, and a private right of action for the minor or the minor’s parent, guardian, or caretaker. It also bars penalties against the minor or the minor’s family, includes rules that resolve ambiguities against defendants, and extends the limitations period for civil suits. In addition, the bill would establish a Treasury fund for “Victims of Gender Transition Procedures Compensation” and authorize grants to private nonprofit entities that provide detransition-related counseling, referrals, medical advice, education and employment assistance, and voluntary mental health or substance use disorder services.
The bill would significantly affect federal health law and medical practice by preempting or overriding any contrary standards of care for minors in this area, at least for purposes of federal enforcement and civil liability. It would also create new compliance and litigation exposure for health care professionals, clinics, employers, and others involved in transition-related care, while expressly preserving the ability of professionals to provide information, counseling, referrals, and opinions so long as they do not participate in a prohibited procedure. The grant provisions would also restrict eligible recipients by excluding entities that perform, refer for, or counsel in favor of gender transition procedures or abortion, subject to limited exceptions.
The available context shows no recorded votes or committee debate, so there is no documented floor or committee sentiment beyond the bill’s text and sponsorship. Based on the bill itself, the measure is strongly protective of restrictions on pediatric gender-affirming care and strongly supportive of detransition services, indicating a clear policy direction rather than a compromise approach. The overall posture suggests support from sponsors and likely opposition from advocates of gender-affirming care, medical professional groups, and civil liberties or LGBTQ rights stakeholders.
The main points of contention are likely to be the bill’s broad definition of prohibited procedures, its treatment of puberty blockers and hormone therapy, its use of federal civil penalties and private lawsuits, and its framing of gender transition care as harmful or reversible. Additional controversy may arise from the bill’s reliance on interstate-commerce jurisdiction, its retroactive civil liability for past conduct, and its exclusion of entities that provide abortion-related services from grant eligibility. Supporters are likely to emphasize child protection and detransition support, while opponents are likely to argue that the bill interferes with medical judgment, targets transgender minors, and conflicts with accepted standards of care.
The bill would add a new federal prohibition on gender transition procedures for minors and create enforcement, penalty, and civil litigation mechanisms administered through HHS and the Department of Justice. It would also establish a federally funded grant program for detransition-related services and compensation, while affecting health care providers, clinics, employers, and nonprofit service organizations that participate in or support transition-related care.
No votes or committee transcript are provided, so there is no recorded legislative debate to summarize. The bill’s text reflects a strongly anti-transition, pro-detransition policy stance, suggesting support from sponsors and aligned advocates and likely opposition from transgender rights advocates, many medical professionals, and civil liberties groups. Overall, the measure appears highly polarized rather than consensus-driven.
The most notable controversies are the bill’s sweeping definition of “gender transition procedure,” which includes puberty blockers, hormones, and many surgeries, and its application to minors through federal penalties and private lawsuits. Opponents would likely object to the bill’s interference with medical care, retroactive liability, and broad federal reach, while supporters would argue it protects children from irreversible interventions. The grant restrictions tied to abortion and the exclusion of entities that provide or refer for gender transition procedures are also likely to be contested.